adverse cardiovascular events among patients undergoing PCI, but not among patients undergoing CABG, [1, [7] [8] [9] [10] [11] [12] [13] [14] [15] limiting its utility in clinical application. One important limitation of the SS is absence of clinical variables in the scoring algorithm. Patients with equivalent scores may have different short-and long-term outcomes, depending on the presence of comorbidities. [16] To overcome these limitations, attempts have been made to combine clinical-based scores with the SS. [17] [18] [19] [20] The SS-II was recently developed, combining of the anatomical SS with anatomical and clinical variables that have been shown to modify the threshold value of the SS so that equipoise was achieved between CABG and PCI for long-term mortality in patients with left main (LM) and/or three-vessel CAD. [21] In a recent validation study, Xu et al. [22] investigated the long-term prognostic value of the SS-II in patients with LM CAD undergoing PCI. In patients with three-vessel disease but no LM involvement, especially undergoing contemporary PCI with second-generation drug-eluting stents (DES), however, the predictive value of the SS-II for long-term mortality has not been evaluated. The purpose of this study is to assess the ability of the SS-II to predict 5-year mortality in patients with three-vessel disease exclusively treated with second-generation DES.
MetHods

Study design and patient population
From December 2008 to January 2010, 573 consecutive patients with de novo three-vessel CAD undergoing PCI and exclusively treated with second-generation DES including zotarolimus-eluting stent ENDEAVOR, zotarolimus-eluting stent RESOLUTE (Medtronic Inc., Santa Rosa, California, USA), and everolimus-eluting stent (Abbott Vascular, Santa Clara, California, USA) in Beijing Anzhen Hospital, China were retrospectively analyzed. Patients with previous PCI or CABG or presenting with acute myocardial infarction (MI) were excluded. Patients were pretreated with 100 mg/d of aspirin and a loading dose of 300 mg of clopidogrel or 75 mg/d clopidogrel for at least 3-day prior to PCI. After the procedure 100 mg/d of aspirin and 75 mg/d of clopidogrel in combination were continued for at least 12 months, aspirin alone was used indefinitely. Follow-up clinical status was documented through hospital records review, telephone interviews, or office visits to the outpatient clinic after the index procedure.
SYNergy between percutaneous coronary intervention with TAXus and Cardiac Surgery score II
The SS-II has been described in detail previously. [22] Briefly, in the present study, the baseline SS was calculated using dedicated software as previously reported, [5] and according to the predefined algorithm, points were added taking into account 6 other clinical variables (age, sex, left ventricular ejection fraction, creatinine clearance, chronic obstructive pulmonary disease, and peripheral vascular disease) leading to the SS-II. The baseline SS for each angiogram was assessed by two experienced investigators who were blinded as to procedural data and clinical outcome. In case of disagreement, the opinion of a third observer was obtained, and the final decision was made by consensus. According to tertiles of the SS-II for PCI, the patients were divided into three groups: The lowest SS-II tertile, intermediate SS-II tertile, and the highest SS-II tertile.
Study endpoints
The primary objective of the present study was to evaluate the impact of the SS-II for PCI on the risk of all-cause mortality in patients with three-vessel disease undergoing PCI. The primary endpoint of this analysis was all-cause mortality at 5-year follow-up. The secondary endpoints included the rates of cardiac death, MI, cerebrovascular event, any repeat revascularization, and major adverse cardiac and cerebrovascular events (MACCE) defined as a composite of all-cause death, cerebrovascular event, MI, and repeated revascularization. Death was defined as any postprocedural death and was considered of cardiac origin unless there was documentation of another cause. A cerebrovascular event was defined as an ischemic neurologic deficit lasting more than 24 h. Repeated revascularization was defined as a subsequent revascularization procedure by percutaneous intervention or surgery after PCI.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) and were compared using the Student's t-test or the Mann-Whitney rank sum test when appropriate. Categorical data are expressed as frequency (percent) and were compared with the Chi-square or Fisher's exact test. Survival curves were generated for time-to-event variables using Kaplan-Meier estimates, and differences in survival were compared using the log-rank test. Patients lost to follow-up were considered at risk until the date of last contact, at which point they were censored. In addition to SS-II risk score, relationships of all-cause death to covariates, utilizing previously published baseline and peri-and post-procedural characteristics, were investigated with univariate Cox regression models. The statistically significant correlates of worse prognosis identified in univariable analyses were then introduced into a multivariable model using the forced enter method, with a variable entry criterion of 0.05. Receiver operator characteristic (ROC) curves were constructed to assess the predictive accuracy of the SS-II for 5-year all-cause mortality. The minimized absolute value of sensitivity-specificity was chosen as the optimal ROC cut-off point. All tests were two-tailed, and a P < 0.05 was considered as statistically significant. All analyses were performed using SPSS 17.0 for Windows (SPSS, Inc., Chicago, IL, USA).
Results
Baseline clinical, angiographic and procedural characteristics
Among the entire cohort, the mean ± SD of the overall SS and SS-II were 26.8 ± 11.5 and 27.6 ± 9.0, respectively.
According to the tertiles of SS-II, the patients were divided into three groups: The lowest SS-II tertile (SS-II ≤ 20), intermediate SS-II tertile (SS-II of 21-31), and the highest SS-II tertile (SS-II ≥ 32). Baseline clinical, angiographic, and procedural characteristics of the study population, stratified according to SS-II tertiles, are shown in Table 1 . Compared with patients in the lower tertile, those in the upper tertile were older, more frequently female, and with higher incidence of hypertension, and diabetes. They were also more likely to have had a previous MI, peripheral vascular disease, or stroke and were more often nonsmokers with lower pre-PCI creatinine clearance. In addition, the mean number of diseased lesions, treated lesions, and stents per patient in those in the upper tertile were significantly higher compared with that of those in the lower tertile as shown in Table 1 .
Long-term follow-up outcome
Among the 573 eligible patients enrolled, 41 patients were lost to follow-up, and clinical data were obtained in 92.8% of the overall cohort. At 5-year follow-up, the rates of all-cause death, cardiac death, MI, stroke, any repeat revascularization, and MACCE in the overall cohort were 4.4%, 2.4%, 6.6%, 3.7%, 21.8%, and 27.7%, respectively. Clinical outcomes stratified according to SS-II tertiles are shown in Table 2 and Figure 1a- Table 3 .
Receiver operator characteristic analysis
Receiver operator characteristic curve analysis showed a significant association between the SS-II and 5-year all-cause mortality with an area under the curve (AUC) of 0.705 (95% CI: 0.599-0.811, P = 0.001). The AUC demonstrated a substantially higher predictive accuracy of the SS-II for 5-year all-cause death, compared with the anatomical SS alone (AUC = 0.598, 95% CI: 0.502-0.694, P = 0.003) as shown in Figure 2 .
disCussion
To the best of our knowledge, the current study is the first to evaluate specifically the SS-II for prediction of long-term mortality in patients with three-vessel disease exclusively treated with second-generation DES. The following are The incidences of 5-year all-cause death, cardiac death, MI, and MACCE were significantly higher in the upper SS-II tertile than in the lower 2 tertiles. However, the rate of 5-year stroke was not significantly different among SS-II tertiles.
The anatomical SS is an important instrument in helping clinicians to establish the optimum revascularization approach in patients with complex CAD. [1] [2] [3] [4] [5] However, the absence of clinical variables to guide decision-making between CABG and PCI is a major limitation of the SS. In previous reports, other scoring systems combining both the anatomical SS and clinical variables (such as the global risk classification, the clinical SS, and the logistic clinical SS, etc.) have been shown to have superior ability in predicting adverse outcomes than the SS alone in patients with complex CAD undergoing PCI. [17] [18] [19] [20] Recently, the SS-II was developed by incorporating clinical variables into anatomical SS and thereby allowing individualized approach to mortality prediction. It was internally validated in the SYNTAX trial and externally validated in the DELTA registry. [21] In patients with unprotected LM disease, the EXCEL study [23] demonstrated that the SS-II can predict 4-year mortality in both PCI and CABG arms, and forecasted at least an equipoise for long-term mortality between CABG and PCI. In the another study, Xu et al. [22] reported that the SS-II possesses better long-term predictive power, mainly in terms of 4-year mortality, compared with the SS alone. Similar results were reported by Farooq et al. [21] and Campos et al. [24] although the population of their studies were patients with LM and/or three-vessel disease undergoing PCI. The result of the present study is consistent with that of the studies mentioned above. However, there are several notable differences: (1) Different study population. In the EXCEL study, [23] study population were a cohort of subjects with LM disease only and low-intermediate anatomical SS (<33). The subjects of our study were patients with three-vessel disease only but no LM involvement. The SS in the present study was higher than that in the studies of Xu et al. [22] and Campos et al., [24] representing anatomically more complex CAD. The higher SS may also reflect a patient population with more advanced systemic atherosclerosis and, therefore, are at greater longer-term cardiovascular and cerebrovascular risk. (2) The use of different stents. Second-generation DES were developed to overcome safety concerns with first-generation devices, and many data suggest significantly improved clinical outcomes in patients undergoing PCI with these new stents. [25] [26] [27] Some studies even demonstrated remarkably lower long-term mortality with second-generation DES as compared with first-generation DES. [28] [29] [30] Presently, second-generation DES were widely applied in patients with CAD undergoing PCI in clinical practice. With the exception of the EXCEL study, [23] all other previous studies [21, 22, 24] have enrolled patients entirely or mostly treated with first-generation DES. Some even included a small amount of bare metal stents. Therefore, the ability of the SS-II to predict long-term mortality in patients treated with second-generation DES implantation remains unknown. The result of the current study confirms the ability of the SS-II to independently predict long-term mortality in patients treated with second-generation DES. It provides important evidence to support the use of the SS-II in contemporary practice. (3) Different duration of follow-up. Our study evaluated the ability of the SS-II to predict 5-year mortality in patients with three-vessel disease undergoing PCI. To the best of our knowledge, this is the longest duration of follow-up among similar previous studies.
[ [21] [22] [23] [24] 
Study limitations
The current study has some limitations. First, it is a retrospective study. As a retrospective analysis, the results should be considered hypothesis generating. Second, it represents a single-center experience, which may affect the generalizability of our findings. In addition, the relatively small number of patients, further diminished by separation into SS-II tertiles, may influence the results. Third, the decision for PCI is based on the clinical judgment of the treating cardiologists, and thus may lead to selection bias. Fourth, although multivariable adjustments were performed for significant confounders (P < 0.05), the possibility of other unmeasured confounders affecting the results cannot be excluded. In addition, as all correlates that were significantly associated with increased mortality on univariable analyses were included in the multivariable model, this may have resulted in over-fitting. Fifth, the calculation of the anatomical SS is associated with inter and intraobserver variability, which is inherent in the subjective nature of its derivation from coronary angiography. Finally, there is no CABG comparative arm with three-vessel disease in this study.
In conclusion, in patients with three-vessel disease but no LM involvement undergoing PCI with second-generation DES, the SS-II is an independent and superior predictor of 5-year mortality, compared with the anatomical SS alone. As such, the SS-II may be a useful instrument for risk stratification in this patient population. Receiver-operating characteristic curve analyses comparing the SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery score (SS) with the SS-II for the predictability of long-term mortality.
